Brokerages Expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Will Post Earnings of $0.05 Per Share

Equities analysts expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) to report earnings of $0.05 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Tabula Rasa HealthCare’s earnings, with the highest EPS estimate coming in at $0.10 and the lowest estimate coming in at $0.01. Tabula Rasa HealthCare reported earnings of $0.22 per share in the same quarter last year, which would indicate a negative year over year growth rate of 77.3%. The company is expected to report its next earnings results on Thursday, November 5th.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.19 per share for the current financial year, with EPS estimates ranging from $0.02 to $0.28. For the next year, analysts forecast that the company will report earnings of $0.61 per share, with EPS estimates ranging from $0.23 to $0.72. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Tuesday, August 4th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.29. Tabula Rasa HealthCare had a negative return on equity of 7.37% and a negative net margin of 14.70%. The firm had revenue of $76.80 million for the quarter, compared to analyst estimates of $78.12 million. During the same quarter in the prior year, the company earned $0.35 EPS. Tabula Rasa HealthCare’s revenue was up .7% on a year-over-year basis.

TRHC has been the topic of several recent research reports. Royal Bank of Canada reiterated a “buy” rating and set a $57.00 target price on shares of Tabula Rasa HealthCare in a research report on Wednesday. SunTrust Banks started coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, July 2nd. They set a “buy” rating and a $72.00 target price on the stock. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Thursday, August 6th. Truist Financial lowered their price target on shares of Tabula Rasa HealthCare from $72.00 to $61.00 in a report on Wednesday, August 12th. Finally, SVB Leerink lowered their price target on shares of Tabula Rasa HealthCare from $65.00 to $56.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Tabula Rasa HealthCare has an average rating of “Buy” and an average price target of $63.27.

In other news, Director Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $56.02, for a total value of $56,020.00. Following the completion of the sale, the director now owns 12,989 shares in the company, valued at approximately $727,643.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Calvin H. Knowlton sold 16,000 shares of Tabula Rasa HealthCare stock in a transaction on Monday, August 10th. The shares were sold at an average price of $48.62, for a total transaction of $777,920.00. Following the completion of the sale, the chief executive officer now owns 764,881 shares of the company’s stock, valued at approximately $37,188,514.22. The disclosure for this sale can be found here. Insiders sold a total of 67,140 shares of company stock valued at $3,353,638 in the last quarter. 11.60% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in TRHC. Principal Financial Group Inc. lifted its holdings in Tabula Rasa HealthCare by 2.6% in the second quarter. Principal Financial Group Inc. now owns 153,028 shares of the company’s stock worth $8,375,000 after acquiring an additional 3,882 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Tabula Rasa HealthCare by 20.6% in the second quarter. PNC Financial Services Group Inc. now owns 6,571 shares of the company’s stock valued at $359,000 after purchasing an additional 1,124 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Tabula Rasa HealthCare by 9.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 146,865 shares of the company’s stock valued at $8,038,000 after buying an additional 12,816 shares during the period. Bank of America Corp DE lifted its stake in Tabula Rasa HealthCare by 2.8% in the second quarter. Bank of America Corp DE now owns 627,777 shares of the company’s stock valued at $34,358,000 after acquiring an additional 17,257 shares during the last quarter. Finally, Stifel Financial Corp lifted its stake in Tabula Rasa HealthCare by 25.9% in the second quarter. Stifel Financial Corp now owns 8,846 shares of the company’s stock valued at $484,000 after acquiring an additional 1,819 shares during the last quarter.

NASDAQ:TRHC traded down $0.40 during mid-day trading on Wednesday, hitting $38.60. 366,458 shares of the company’s stock were exchanged, compared to its average volume of 358,468. The company has a 50 day simple moving average of $47.39 and a 200-day simple moving average of $53.23. The company has a current ratio of 2.41, a quick ratio of 2.31 and a debt-to-equity ratio of 1.34. Tabula Rasa HealthCare has a fifty-two week low of $33.04 and a fifty-two week high of $69.72. The firm has a market capitalization of $886.26 million, a P/E ratio of -18.74 and a beta of 0.99.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

See Also: FTSE 100 Index

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit